{
  "id": 6562691,
  "title": "Genuro at Moody Capital Disruptive Growth & Life Science Conference: ALS bet",
  "url": "https://urgent.news/2026/09/10/genuro-at-moody-capital-disruptive-growth-life-science-conference-als",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-10T08:30:18.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/genuro-at-moody-capital-disruptive-growth--life-science-conference-als-bet-93CH-4895135"
  },
  "original_language": "en",
  "account": "On September 9, 2026, biotech company Genuro made its debut at the Moody Capital Disruptive Growth & Life Science Conference to discuss its high-stakes approach to treating amyotrophic lateral sclerosis (ALS) through the study of human endogenous retroviruses (HERVs). Genuro's lead ALS program is targeting a potential human-grade drug supply by July 2027, but acknowledges significant scientific and execution uncertainties. The company believes HERVs, which make up around 8% of the human genome, may play a role in the development of ALS, multiple sclerosis, and schizophrenia.\n\nGenuro is developing a monoclonal antibody-based approach to neutralize HERV-K and HERV-W envelope proteins, which can become harmful when dysregulated in adulthood. The company is working with manufacturing partner Polymun and has secured $80 million in funding through the 2027 U.S. defense appropriations bill and Congressionally Directed Medical Research Programs. Genuro's initial focus is on ALS, with potential extensions to other HERV-related conditions like multiple sclerosis and schizophrenia.\n\nThe company has €180 million in prior European R&D, 25 approved patents, and a clean cap table after acquiring assets from a Swiss bankruptcy. Genuro's manufacturing plan, led by Mike Taylor and Rick Panicucci, aims to produce a human-grade drug product by July 2027. The timeline and funding sources make Genuro one of the most advanced ALS programs in the pipeline, with a potential FDA approval by 2029.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}